Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/181427
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPoh, Xuan Yingen_US
dc.contributor.authorLee, I. Russelen_US
dc.contributor.authorTan, Chee Wahen_US
dc.contributor.authorChavatte, Jean-Marcen_US
dc.contributor.authorFong, Siew Waien_US
dc.contributor.authorGoh, Yun Shanen_US
dc.contributor.authorRouers, Angelineen_US
dc.contributor.authorWong, Nathanen_US
dc.contributor.authorTorres-Ruesta, Anthonyen_US
dc.contributor.authorMah, Shirley Y. Y.en_US
dc.contributor.authorYeoh, Aileen Y. Y.en_US
dc.contributor.authorGandhi, Mihiren_US
dc.contributor.authorRahman, Nabilahen_US
dc.contributor.authorChin, Yi Qingen_US
dc.contributor.authorLim, J Jonathanen_US
dc.contributor.authorYoong, Terence J. K.en_US
dc.contributor.authorRao, Sumaen_US
dc.contributor.authorChia, Po Yingen_US
dc.contributor.authorOng, Sean W. X.en_US
dc.contributor.authorLee, Tau Hongen_US
dc.contributor.authorSadarangani, Sapna P.en_US
dc.contributor.authorLin, Ray J. H.en_US
dc.contributor.authorLim, Daniel R. X.en_US
dc.contributor.authorChia, Wannien_US
dc.contributor.authorRenia, Laurenten_US
dc.contributor.authorRen, Ee Cheeen_US
dc.contributor.authorLin, Raymond T. P.en_US
dc.contributor.authorLye, David C.en_US
dc.contributor.authorWang, Lin-Faen_US
dc.contributor.authorNg, Lisa F. P.en_US
dc.contributor.authorYoung, Barnaby Edwarden_US
dc.date.accessioned2024-12-02T05:15:34Z-
dc.date.available2024-12-02T05:15:34Z-
dc.date.issued2024-
dc.identifier.citationPoh, X. Y., Lee, I. R., Tan, C. W., Chavatte, J., Fong, S. W., Goh, Y. S., Rouers, A., Wong, N., Torres-Ruesta, A., Mah, S. Y. Y., Yeoh, A. Y. Y., Gandhi, M., Rahman, N., Chin, Y. Q., Lim, J. J., Yoong, T. J. K., Rao, S., Chia, P. Y., Ong, S. W. X., ...Young, B. E. (2024). First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial. EBioMedicine, 107, 105275-. https://dx.doi.org/10.1016/j.ebiom.2024.105275en_US
dc.identifier.issn2352-3964en_US
dc.identifier.urihttps://hdl.handle.net/10356/181427-
dc.description.abstractBackground: Understanding how SARS-CoV-2 breakthrough infections impacts the breadth of immune responses against existing and pre-emergent SARS-CoV-2 strains is needed to develop an evidence-based long-term immunisation strategy. Methods: We performed a randomised, controlled trial to assess the immunogenicity of homologous (BNT162b2) versus heterologous (mRNA-1273) booster vaccination in 100 BNT162b2-vaccinated infection-naïve individuals enrolled from October 2021. Post hoc analysis was performed to assess the impact of SARS-CoV-2 infection on humoral and cellular immune responses against wild-type SARS-CoV-2 and/or Omicron subvariants. Findings: 93 participants completed the study at day 360. 71% (66/93) of participants reported first SARS-CoV-2 Omicron infection by the end of the study with similar proportions of infections between homologous and heterologous booster groups (72.3% [34/47] vs 69.6% [32/46]; p = 0.82). Mean wildtype SARS-CoV-2 anti-S-RBD antibody level was significantly higher in heterologous booster group compared with homologous group at day 180 (14,588 IU/mL; 95% CI, 10,186–20,893 vs 7447 IU/mL; 4646–11,912; p = 0.025). Participants who experienced breakthrough infections during the Omicron BA.1/2 wave had significantly higher anti-S-RBD antibody levels against wildtype SARS-CoV-2 and antibody neutralisation against BA.1 and pre-emergent BA.5 compared with infection-naïve participants. Regardless of hybrid immunity status, wildtype SARS-CoV-2 anti-S-RBD antibody level declined significantly after six months post-booster or post-SARS-CoV-2 infection. Interpretation: Booster vaccination with mRNA-1273 was associated with significantly higher antibody levels compared with BNT162b2. Antibody responses are narrower and decline faster among uninfected, vaccinated individuals. Boosters may be more effective if administered shortly before infection outbreaks and at least six months after last infection or booster.en_US
dc.description.sponsorshipAgency for Science, Technology and Research (A*STAR)en_US
dc.description.sponsorshipMinistry of Education (MOE)en_US
dc.description.sponsorshipNational Medical Research Council (NMRC)en_US
dc.language.isoenen_US
dc.relationSTPRG-FY19-001en_US
dc.relationCOVID19RF-003en_US
dc.relationCOVID19RF-011en_US
dc.relationCOVID19RF-018en_US
dc.relationCOVID19RF-060en_US
dc.relationOFLCG19May-0034en_US
dc.relationACCL/19-GAP064-R20H-Hen_US
dc.relationH/20/04/g1/006en_US
dc.relationSUJ #022388-00001en_US
dc.relationCSAINV22jul-0015en_US
dc.relation.ispartofEBioMedicineen_US
dc.rights© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectMedicine, Health and Life Sciencesen_US
dc.titleFirst SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.contributor.organizationNational Centre for Infectious Diseases, Singaporeen_US
dc.contributor.organizationTan Tock Seng Hospitalen_US
dc.contributor.organizationA*STAR Infectious Diseases Labsen_US
dc.contributor.organizationYong Loo Lin School of Medicine, NUSen_US
dc.identifier.doi10.1016/j.ebiom.2024.105275-
dc.description.versionPublished versionen_US
dc.identifier.pmid39137572-
dc.identifier.scopus2-s2.0-85200952064-
dc.identifier.volume107en_US
dc.identifier.spage105275en_US
dc.subject.keywordsCellular responseen_US
dc.subject.keywordsCOVID-19 boosteren_US
dc.description.acknowledgementThe study is supported in part by grants from Singapore’s National Medical Research Council (NMRC) [STPRG-FY19-001, COVID19RF-003, COVID19RF-011, COVID19RF-018, COVID19RF-060 and OFLCG19May-0034], the Biomedical Research Council, A*CRUSE (Vaccine monitoring project), A*ccelerate GAP-funded project (ACCL/19-GAP064-R20H-H) from Agency for Science, Technology and Research (A*STAR), A*STAR COVID-19 Research funding (H/20/04/g1/006), A*STAR Career Development Fund to YS Goh (SC35/22- 805100), U.S. Food and Drug Administration (#75F40120C00085) and by a Start-up University Grant from the Singapore Ministry of Education to L Renia (SUJ #022388-00001). BY is also supported by NMRC via CSAINV22jul-0015.en_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
PIIS2352396424003116.pdf2.18 MBAdobe PDFThumbnail
View/Open

Page view(s)

52
Updated on Feb 7, 2025

Download(s)

5
Updated on Feb 7, 2025

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.